Loading...
Everolimus downregulates estrogen receptor and induces autophagy in aromatase inhibitor-resistant breast cancer cells
BACKGROUND: mTOR inhibition of aromatase inhibitor (AI)-resistant breast cancer is currently under evaluation in the clinic. Everolimus/RAD001 (Afinitor®) has had limited efficacy as a solo agent but is projected to become part of combination therapy for AI-resistant breast cancer. This study was co...
Na minha lista:
| Udgivet i: | BMC Cancer |
|---|---|
| Main Authors: | , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
BioMed Central
2016
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4947349/ https://ncbi.nlm.nih.gov/pubmed/27421652 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-016-2490-z |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|